Glenmark Pharma Q2 FY27: Net profit falls 57% to ₹264 crore, revenue drops 30%
Synopsis
Glenmark Pharmaceuticals' headline Q2 FY27 numbers look alarming — profit down 57%, revenue down 30% — but the real story is a base-effect distortion from last year's deferred out-licensing income. Strip that out, and North America grew 31%, emerging markets 33%, and India formulations 14%. The question is whether Glenmark's innovation pipeline can deliver the next earnings catalyst before investor patience wears thin.
Key Takeaways
Glenmark Pharmaceuticals reported Q2 FY27 net profit of ₹264 crore , down 56.7 per cent year-on-year from ₹610 crore .
Revenue from operations fell 29.8 per cent to ₹4,247.3 crore from ₹6,046.8 crore in Q2 FY26.
EBITDA declined 63.4 per cent to ₹864 crore ; EBITDA margin compressed to 20 per cent from 39 per cent .
India formulations grew 14 per cent YoY; emerging markets surged 33.2 per cent to ₹876.9 crore .
Core North America business grew ~ 31 per cent YoY excluding deferred out-licensing income impact.
Phase 1 data for ISB 2001 selected for oral presentation at the 2026 ASH Annual Meeting ; first oncology product launch expected by end of FY27 .
Glenmark Pharmaceuticals posted a steep 56.7 per cent year-on-year decline in consolidated net profit to ₹264 crore for the second quarter of FY27 (July–September 2026), compared with ₹610 crore in the same period last year, according to the company's stock exchange filing. Revenue from operations fell sharply as well, casting a shadow over an otherwise resilient underlying business.
Key Financial Highlights
Revenue from operations dropped 29.8 per cent to ₹4,247.3 crore in Q2 FY27, down from ₹6,046.8 crore in Q2 FY26. Earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 63.4 per cent to ₹864 crore from ₹2,360 crore, with the EBITDA margin contracting sharply to 20 per cent from 39 per cent a year earlier. The company attributed a significant portion of the year-on-year variance to the non-recurrence of deferred out-licensing income recognised in the prior-year period, particularly related to ISB 2001.
Segment Performance
Not all segments were under pressure. The India formulations business delivered a standout performance, with revenue rising to ₹1,327.4 crore and registering like-for-like growth of approximately 14 per cent year-on-year. In North America, reported revenue stood at ₹1,208.9 crore; however, the company noted that excluding the base effect of the deferred ISB 2001 out-licensing income, core North American business grew around 31 per cent year-on-year. European operations held steady, with revenue increasing 6.2 per cent to ₹792 crore, while emerging markets delivered the strongest segment growth at 33.2 per cent, taking revenue to ₹876.9 crore.
Innovation and Pipeline Progress
Glenmark's respiratory brand RYALTRIS continued its global expansion, with a recent launch in Brazil marking a new geographic milestone. The company's partnered oncology pipeline is advancing toward commercialisation, with the first product launch expected by the end of FY27. The innovation subsidiary IGI is making progress on its multispecific oncology pipeline — Phase 1 data for ISB 2001 has been selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, and the company plans to file an investigational new drug (IND) application for ISB 2301 before the close of the calendar year.
Management Outlook and Market Reaction
Despite the headline decline in earnings, Glenmark's management affirmed that the underlying business remained resilient and reiterated that the company is on track to meet its FY27 annual guidance. Shares of Glenmark Pharmaceuticals ended 0.65 per cent lower at ₹2,485.50 on the Bombay Stock Exchange (BSE) ahead of the earnings announcement. The muted market reaction suggests investors had largely priced in the base-effect drag from the high-income quarter a year ago. All eyes will now turn to the second half of FY27, when fresh pipeline milestones and emerging-market momentum could help restore margin optics.
Point of View
But the comparison base is deeply distorted by last year's one-time out-licensing income from ISB 2001 — a fact the company buried in the segmental commentary rather than the headline. Stripping that out reveals a company whose operating businesses are actually gaining traction across all geographies. The more uncomfortable question is margin: EBITDA at 20 per cent against a 39 per cent base a year ago is a structural flag, not just a base-effect artefact, and investors will want management to explain the path back toward the mid-to-upper twenties. The pipeline narrative around ASH 2026 and the oncology commercialisation timeline adds optionality, but Glenmark has a history of promising innovation cycles that take longer than guided.
NationPress
5 Nov 2026
Frequently Asked Questions
Why did Glenmark Pharmaceuticals' Q2 FY27 profit fall so sharply?
Glenmark's consolidated net profit fell 56.7 per cent year-on-year to ₹264 crore in Q2 FY27, primarily because the year-ago quarter (Q2 FY26) included high deferred out-licensing income related to ISB 2001, creating a tough base. Excluding that one-time item, core business segments such as North America and emerging markets recorded strong growth.
How did Glenmark's India business perform in Q2 FY27?
The India formulations business was a bright spot, with revenue rising to ₹1,327.4 crore and like-for-like growth of approximately 14 per cent year-on-year — one of the strongest domestic performances in recent quarters.
What is Glenmark's FY27 guidance?
The company said its underlying business remained resilient and reiterated that it is on track to meet its full-year FY27 guidance, though it did not provide revised numerical targets in the quarterly filing.
What is ISB 2001 and why does it matter to Glenmark's earnings?
ISB 2001 is a multispecific oncology antibody being developed by Glenmark's innovation subsidiary IGI. Deferred out-licensing income related to ISB 2001 boosted revenue and profit in Q2 FY26, making year-on-year comparisons for Q2 FY27 unfavourable. Phase 1 data for ISB 2001 has been selected for oral presentation at the 2026 ASH Annual Meeting.
How did Glenmark shares react to the Q2 FY27 results?
Shares of Glenmark Pharmaceuticals ended 0.65 per cent lower at ₹2,485.50 on the BSE ahead of the earnings announcement, suggesting markets had largely anticipated the results.
